GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:015010516 | Oral cavity | NEOLP | protein localization to cell-cell junction | 8/2005 | 21/18723 | 9.62e-04 | 7.39e-03 | 8 |
GO:005197232 | Oral cavity | NEOLP | regulation of telomerase activity | 13/2005 | 47/18723 | 9.97e-04 | 7.65e-03 | 13 |
GO:000974624 | Oral cavity | NEOLP | response to hexose | 39/2005 | 219/18723 | 1.00e-03 | 7.68e-03 | 39 |
GO:001988332 | Oral cavity | NEOLP | antigen processing and presentation of endogenous antigen | 9/2005 | 26/18723 | 1.04e-03 | 7.95e-03 | 9 |
GO:003134922 | Oral cavity | NEOLP | positive regulation of defense response | 47/2005 | 278/18723 | 1.05e-03 | 7.99e-03 | 47 |
GO:004858822 | Oral cavity | NEOLP | developmental cell growth | 41/2005 | 234/18723 | 1.05e-03 | 8.00e-03 | 41 |
GO:00032814 | Oral cavity | NEOLP | ventricular septum development | 17/2005 | 71/18723 | 1.10e-03 | 8.28e-03 | 17 |
GO:003803412 | Oral cavity | NEOLP | signal transduction in absence of ligand | 16/2005 | 65/18723 | 1.11e-03 | 8.33e-03 | 16 |
GO:009719212 | Oral cavity | NEOLP | extrinsic apoptotic signaling pathway in absence of ligand | 16/2005 | 65/18723 | 1.11e-03 | 8.33e-03 | 16 |
GO:000941024 | Oral cavity | NEOLP | response to xenobiotic stimulus | 71/2005 | 462/18723 | 1.12e-03 | 8.45e-03 | 71 |
GO:0045214 | Oral cavity | NEOLP | sarcomere organization | 12/2005 | 42/18723 | 1.13e-03 | 8.46e-03 | 12 |
GO:005105113 | Oral cavity | NEOLP | negative regulation of transport | 72/2005 | 470/18723 | 1.14e-03 | 8.49e-03 | 72 |
GO:19050373 | Oral cavity | NEOLP | autophagosome organization | 22/2005 | 103/18723 | 1.16e-03 | 8.66e-03 | 22 |
GO:20008111 | Oral cavity | NEOLP | negative regulation of anoikis | 7/2005 | 17/18723 | 1.18e-03 | 8.72e-03 | 7 |
GO:200037731 | Oral cavity | NEOLP | regulation of reactive oxygen species metabolic process | 30/2005 | 157/18723 | 1.18e-03 | 8.72e-03 | 30 |
GO:004544521 | Oral cavity | NEOLP | myoblast differentiation | 19/2005 | 84/18723 | 1.20e-03 | 8.85e-03 | 19 |
GO:003362713 | Oral cavity | NEOLP | cell adhesion mediated by integrin | 17/2005 | 72/18723 | 1.29e-03 | 9.43e-03 | 17 |
GO:200057331 | Oral cavity | NEOLP | positive regulation of DNA biosynthetic process | 16/2005 | 66/18723 | 1.32e-03 | 9.48e-03 | 16 |
GO:006021331 | Oral cavity | NEOLP | positive regulation of nuclear-transcribed mRNA poly(A) tail shortening | 6/2005 | 13/18723 | 1.32e-03 | 9.48e-03 | 6 |
GO:190121431 | Oral cavity | NEOLP | regulation of neuron death | 52/2005 | 319/18723 | 1.37e-03 | 9.77e-03 | 52 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TG | SNV | Missense_Mutation | rs201480815 | c.3416N>T | p.Ser1139Leu | p.S1139L | P01266 | protein_coding | tolerated(0.14) | benign(0) | TCGA-A1-A0SK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
TG | SNV | Missense_Mutation | | c.4662G>T | p.Trp1554Cys | p.W1554C | P01266 | protein_coding | deleterious(0.01) | benign(0.123) | TCGA-A1-A0SP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | | SD |
TG | SNV | Missense_Mutation | | c.4882N>T | p.Asp1628Tyr | p.D1628Y | P01266 | protein_coding | deleterious(0) | possibly_damaging(0.861) | TCGA-A2-A04W-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
TG | SNV | Missense_Mutation | | c.3133N>A | p.Gly1045Arg | p.G1045R | P01266 | protein_coding | tolerated(0.13) | benign(0.007) | TCGA-A2-A25B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | PD |
TG | SNV | Missense_Mutation | | c.5223N>C | p.Gln1741His | p.Q1741H | P01266 | protein_coding | deleterious(0.02) | probably_damaging(0.994) | TCGA-A2-A25B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | PD |
TG | SNV | Missense_Mutation | rs773795717 | c.4645C>T | p.Arg1549Trp | p.R1549W | P01266 | protein_coding | deleterious(0.05) | benign(0.232) | TCGA-A7-A13E-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | bevacizumab | PD |
TG | SNV | Missense_Mutation | novel | c.1093N>A | p.Ala365Thr | p.A365T | P01266 | protein_coding | tolerated(0.44) | benign(0) | TCGA-A7-A26I-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD |
TG | SNV | Missense_Mutation | rs146594373 | c.4268N>A | p.Arg1423His | p.R1423H | P01266 | protein_coding | tolerated(0.55) | benign(0.001) | TCGA-A8-A06O-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | letrozole | SD |
TG | SNV | Missense_Mutation | | c.746G>A | p.Gly249Asp | p.G249D | P01266 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A8-A07L-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | | CR |
TG | SNV | Missense_Mutation | | c.3746N>T | p.Cys1249Phe | p.C1249F | P01266 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A8-A08F-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | | RETINOIDS | | 12182039 |
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | | FDG | FLUDEOXYGLUCOSE-F18 | 10452315 |
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | | BISPECIFIC ANTIBODY | | 10433080 |
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | | PHENYTOIN | PHENYTOIN | 3935423 |
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | | PREDNISONE | PREDNISONE | 2745931 |
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | | ALL-TRANS-RETINOIC ACID | | 10946899 |
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | | TGFBETA1 | | 10770487,10194419 |
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | | RETINOIC ACID | | 11563543 |
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | | PREDNISOLONE | PREDNISOLONE | 3427792,8636270 |
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | | AMIODARONE | AMIODARONE | 8778159 |